| 1.1 Achievement of clinical remission |
3 |
148 |
Risk Ratio (M‐H, Random, 95% CI) |
3.76 [1.03, 13.73] |
| 1.1.1 Oral tacrolimus – low target serum concentration of tacrolimus: 5–10 ng/mL |
1 |
33 |
Risk Ratio (M‐H, Random, 95% CI) |
2.29 [0.12, 43.84] |
| 1.1.2 Oral tacrolimus – high target serum concentration of tacrolimus: 10–15 ng/mL |
2 |
94 |
Risk Ratio (M‐H, Random, 95% CI) |
3.07 [0.57, 16.58] |
| 1.1.3 Rectal tacrolimus vs placebo |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
10.08 [0.63, 162.06] |
| 1.2 Achievement of clinical remission for oral tacrolimus vs placebo (subgroup analysis) |
2 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
2.85 [0.66, 12.35] |
| 1.2.1 Oral tacrolimus – low target serum concentration of tacrolimus: 5–10 ng/mL |
1 |
33 |
Risk Ratio (M‐H, Random, 95% CI) |
2.29 [0.12, 43.84] |
| 1.2.2 Oral tacrolimus – high target serum concentration of tacrolimus: 10–15 ng/mL |
2 |
94 |
Risk Ratio (M‐H, Random, 95% CI) |
3.07 [0.57, 16.58] |
| 1.3 Achievement of clinical remission for rectal tacrolimus vs placebo (subgroup analysis) |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
10.08 [0.63, 162.06] |
| 1.3.1 Rectal tacrolimus versus placebo |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
10.08 [0.63, 162.06] |
| 1.4 Clinical improvement |
3 |
148 |
Risk Ratio (M‐H, Random, 95% CI) |
4.47 [2.15, 9.29] |
| 1.4.1 Low target serum concentration of tacrolimus: 5–10 ng/mL |
1 |
33 |
Risk Ratio (M‐H, Random, 95% CI) |
3.48 [0.50, 24.25] |
| 1.4.2 High target serum concentration of tacrolimus: 10–15 ng/mL |
2 |
94 |
Risk Ratio (M‐H, Random, 95% CI) |
4.25 [1.78, 10.12] |
| 1.4.3 Rectal tacrolimus vs placebo |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
7.27 [1.09, 48.35] |
| 1.5 Clinical improvement for oral tacrolimus vs placebo (subgroup analysis) |
2 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
4.11 [1.86, 9.08] |
| 1.5.1 Low target serum concentration of tacrolimus: 5–10 ng/mL |
1 |
33 |
Risk Ratio (M‐H, Random, 95% CI) |
3.48 [0.50, 24.25] |
| 1.5.2 High target serum concentration of tacrolimus: 10–15 ng/mL |
2 |
94 |
Risk Ratio (M‐H, Random, 95% CI) |
4.25 [1.78, 10.12] |
| 1.6 Clinical improvement for rectal tacrolimus vs placebo (subgroup analysis) |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
7.27 [1.09, 48.35] |
| 1.6.1 Rectal tacrolimus versus placebo |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
7.27 [1.09, 48.35] |
| 1.7 Serious adverse events |
3 |
148 |
Risk Ratio (M‐H, Random, 95% CI) |
2.44 [0.12, 48.77] |
| 1.8 Total adverse events |
3 |
148 |
Risk Ratio (M‐H, Random, 95% CI) |
1.18 [0.91, 1.54] |
